Dosing

Not an actual patient
Convenient once-daily dosing

Convenient once-daily dosing without complex titration1

ONE CAPSULE, ONCE DAILY1

INGREZZA valbenazine once daily 40 mg 80 mg dose INGREZZA® (valbenazine) initial dose
INGREZZA pill icon

INGREZZA® (valbenazine) capsules 80 mg is the recommended dose, but INGREZZA 40 mg may be considered for some patients1

  • Once on INGREZZA 80 mg, adjusting back to 40 mg may be considered based on your patient's individual treatment needs1
  • In clinical trials, investigators could decrease the 80 mg dose once at any time during the study due to tolerability. Patients were discontinued if the new dose was not tolerated2
Target icon

In clinical trials, patients receiving INGREZZA were allowed to remain on their stable treatment regimen2

In KINECT 3, the most common types of concomitant medications were2,3

  • Antipsychotics (85.5%)

  • Antidepressants (66.5%)

  • Anticholinergics (37.0%)

  • Antiepileptics (35.2%)

  • Anxiolytics (27.7%)

  • ACE inhibitors (25.1%)

Stomach icon

INGREZZA can be taken with or without food1

Drug interactions

Choose the appropriate INGREZZA® (valbenazine) capsules dose based on your patient’s needs1

Dosing recommendations for patients with complex medical histories1

Moderate to severe hepatic impairment Recommended dose 40 mg
Known CYP2D6 poor metabolizers Consider dose reduction based on tolerability
Strong CYP3A4 inducers Concomitant use not recommended
Strong CYP3A4 inhibitors Reduce dose to 40 mg
Strong CYP2D6 inhibitors Consider dose reduction based on tolerability
MAOIs Avoid concomitant use
Digoxin Digoxin concentrations should be monitored when coadministered; may need to adjust digoxin dosage
  • MAOIs, monoamine oxidase inhibitors.
In clinical trials, patients receiving INGREZZA were allowed to remain on their stable treatment regimen2
Administration information

INGREZZA® (valbenazine) capsules administration information

Continue to make monitoring a routine part of care for patients with tardive dyskinesia (TD)

Kidney icon

For TD patients with renal impairment1 Dosage adjustment is not necessary for patients with mild to moderate renal impairment (creatinine clearance 30-90 mL/min). INGREZZA does not undergo primary renal clearance. INGREZZA is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min).

Liver icon

For TD patients with hepatic impairment1 Dosage reduction of INGREZZA is recommended for patients with moderate or severe hepatic impairment (Child-Pugh score between 7 and 15). Patients with moderate to severe hepatic impairment had higher exposure of INGREZZA and its active metabolite than patients with normal hepatic function. The recommended dose for patients with moderate or severe hepatic impairment is INGREZZA 40 mg once daily.

Heart icon

For patients with increased cardiac risk1 INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.